The Approval at a Glance

On June 17, 2026, the European Commission formally adopted the Implementing Regulation adding Rhizomucor pusillus mycelium — the fungal biomass behind Fermotein — to the EU's Union List of authorised novel foods under Regulation (EU) 2015/2283. The regulation enters into force 20 days after publication in the Official Journal of the European Union, clearing Fermotein for commercial sale across all 27 member states.

The decision followed a positive scientific opinion published by the European Food Safety Authority (EFSA) in December 2025 and a favourable vote by the Standing Committee on Plants, Animals, Food and Feed in May 2026. The Protein Brewery, a Dutch food technology startup headquartered in Breda, Netherlands, first submitted its regulatory dossier in May 2020 — making the total journey from application to market authorisation just over six years.

The milestone is commercially significant on multiple levels: it is the first time a mycoprotein ingredient has cleared the EU novel food system (as opposed to products with a documented consumption history predating 1997), and it positions Fermotein as the reference regulatory precedent for future fungal biomass submissions across the bloc.

What Fermotein Is — and Why It Matters

Fermotein is a whole-cell bioproduct derived from Rhizomucor pusillus, an extremophilic filamentous fungus already present in traditional fermented foods and widely used in enzyme production for conventional cheesemaking. What The Protein Brewery has commercialised is the use of this strain as a primary nutritional ingredient — grown in industrial fermentation tanks using glucose as a feedstock, then sieved, pasteurised, de-watered, and dried into a neutral-tasting powder.

The nutritional profile is what distinguishes Fermotein in a crowded alternative protein market. The ingredient delivers approximately 50% complete protein with all essential amino acids, a PDCAAS score of 1 (the maximum), and 30% prebiotic dietary fibre — all in a single ingredient, without blending or fortification. Its sensory characteristics — neutral taste, natural colour, and minimal off-notes — give formulators significant latitude. Applications range from high-protein ready-to-drink beverages, nutrition bars, and meal replacers to protein-enriched baked goods, dairy alternatives, and dietary supplements.

Fermotein also operates at the intersection of two high-growth markets: the broader functional nutrition wave and the emerging GLP-1 companion nutrition segment. Its high fibre content supports gut health and satiety — qualities that are increasingly valued by users of weight-management drugs like Ozempic and Wegovy, who face muscle mass loss and require nutrient-dense, high-protein dietary support. This positioning is not incidental: Novo Holdings, the investment vehicle of Novo Nordisk, participated in The Protein Brewery's €30M Series B round.

A Six-Year Regulatory Marathon — and Its Structural Implications

The regulatory timeline for Fermotein is both a cause for celebration and a source of concern for the alternative protein industry. The Protein Brewery submitted its novel food dossier to the European Commission in May 2020. EFSA did not formally begin its assessment until January 2021. The process involved repeated requests for additional safety, compositional, and toxicological studies — at considerable cost and delay — before the agency's Nutrition, Novel Foods and Food Allergens panel ultimately concluded that Fermotein raised no safety or genotoxicity concerns and exhibited low allergenicity.

In contrast, Fermotein had already received self-affirmed GRAS status in the United States in 2021 and secured regulatory approval in Singapore in 2024. Both jurisdictions demonstrated meaningfully faster pathways to market. The EU's six-year timeline — even for a novel food derived from a strain already present in traditional fermented foods and established enzyme production — highlights a structural constraint that disadvantages European food innovators relative to global competitors.

The policy dimension extends beyond a single company. Any alternative protein startup — whether working in mycoprotein, precision fermentation, or cultivated meat — must weigh EU market timelines as a core factor in capital planning, revenue modelling, and competitive sequencing. Extended regulatory timelines raise the cost of innovation, advantage incumbents, and divert investment to jurisdictions with more efficient approval frameworks. For MENA markets considering the development of their own novel food regulatory pathways, this dynamic carries direct strategic lessons.

The Mycoprotein Market: From Niche to Nutritional Infrastructure

Fermotein's approval arrives at an inflection point for the broader mycoprotein category. The global mycoprotein market was valued at approximately $679 million in 2025 and is projected to reach $733 million in 2026, growing at a CAGR of approximately 8.6% toward a $1.2 billion valuation by 2032. The category is no longer primarily defined by Quorn's frozen meat-analogue formats — it is evolving rapidly into a B2B ingredient platform with applications across functional nutrition, sports performance, gut health, and GLP-1 companion products.

Fermotein is positioned at the most differentiated end of this spectrum. Unlike mycoprotein minced products targeting the meat-alternative consumer, Fermotein is a powdered ingredient sold to food manufacturers — making it structurally closer to a functional ingredient platform than a finished food brand. This B2B model reduces retail execution risk and places The Protein Brewery in direct competition with established protein ingredient suppliers including pea, soy, and whey protein manufacturers, as well as emerging precision fermentation players.

The competitive advantage Fermotein presents is the ability to deliver complete protein and high fibre in a single, clean-label, minimally-processed, neutral-tasting ingredient — without the allergen profile of soy or the processing intensity of isolating protein from plant matrices. As food manufacturers face mounting pressure from consumers seeking ingredient simplicity and nutritional density, single-source complete protein ingredients represent a meaningful formulation opportunity.

Commercialisation Roadmap and Global Expansion

With EU authorisation secured, The Protein Brewery's commercial trajectory enters a new phase. The company expects to begin supplying Fermotein to European customers from Q3 2026, direct from its demonstration-scale factory in Breda. Production commitments are in place across European, American, and Singaporean markets, with supply targeted at 600 metric tonnes in 2027, scaling to over 2,000 metric tonnes by 2029 through capacity expansion.

Regulatory submissions are progressing concurrently in the United Kingdom (expected approval later in 2026), Canada, and Australia and New Zealand. In the United States, the company already operates under self-affirmed GRAS status and is awaiting a formal no-further-questions letter from the FDA. This multi-market regulatory strategy reflects a deliberate effort to construct a global ingredient supply business with defensible regulatory moats — the five-year exclusive data protection rights granted by the EU authorisation being a key competitive shield in Europe.

Commercial partnerships announced to date include Nepra Foods and CK Ingredients in North America, with formulation trials underway across meal replacers, protein shakes, nutritional bars, dairy alternatives, and better-for-you snack products. Initial applications targeting health and wellness are expected to expand progressively into mainstream food and beverage categories as production economics improve at scale.

Implications for MENA and the GCC Food Sector

For food technology investors, policymakers, and manufacturers across Saudi Arabia and the wider MENA region, Fermotein's EU approval carries several layers of strategic relevance. The most immediate is market signal: alternative protein ingredients that can demonstrate genuine nutritional completeness, regulatory validation across multiple jurisdictions, and scalable fermentation economics are beginning to clear the highest bars of institutional credibility.

The GCC's food security agenda under Vision 2030 and parallel national food strategies across the region places significant emphasis on diversifying protein supply — reducing dependence on imported animal proteins, which are resource-intensive to produce and susceptible to commodity price volatility and supply chain disruption. Fermentation-derived proteins represent one of the most compelling pathways toward domestically producible, resource-efficient protein supply: the production process is highly controllable, not dependent on agricultural land or seasonal cycles, and can be co-located with industrial food processing infrastructure.

The UAE has already emerged as a regional leader in alternative protein investment. Saudi Arabia's NEOM project and the Kingdom's broader food technology ecosystem are increasingly engaged with precision fermentation and alternative protein innovation. Fermotein's EU approval — and the investment thesis it validates — provides a direct reference point for MENA regulators and investors considering how to structure novel food frameworks that can accelerate, rather than impede, the commercialisation of scientifically validated food innovations.

The Middle East and Africa region held an estimated 9.4% share of the global mycoprotein products market in 2025 and is projected to grow at approximately 8.9% CAGR through 2034, supported by intensifying investments in food innovation and alternative protein production. The UAE leads regional adoption, driven by food security imperatives and a strong appetite for advanced food technologies in urban markets.

Editorial View

The authorisation of Fermotein is a genuine milestone — not merely for The Protein Brewery, but for the broader thesis that precision fermentation can deliver safe, nutritionally superior, and commercially viable ingredients at scale. The EU's approval signals that the most rigorous food safety system in the world is capable of clearing novel biomass fermentation ingredients. That matters enormously for investor confidence and industry credibility.

But the six-year timeline tells an equally important story. The regulatory infrastructure that governs food innovation in the world's largest consumer market is not calibrated for the pace at which the protein transition needs to move. If the EU is serious about its protein diversification goals — and it has articulated those goals explicitly in its Farm to Fork strategy — it must build the regulatory capacity and pre-submission guidance frameworks that allow safe, well-evidenced ingredients to reach the market in two to three years, not six.

For MENA policymakers and food sector strategists, there is a genuine first-mover opportunity. A jurisdiction that builds a rigorous but efficient novel food framework — one that engages applicants early, provides pre-submission scientific guidance, and processes applications within defined timelines — will attract the next generation of alternative protein innovators looking for faster pathways to market. The race for regulatory advantage in food innovation is just beginning.